223 related articles for article (PubMed ID: 24478033)
1. Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).
Romagnuolo R; Marcovina SM; Boffa MB; Koschinsky ML
J Lipid Res; 2014 Apr; 55(4):625-34. PubMed ID: 24478033
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins α
Romagnuolo R; Scipione CA; Bazzi ZA; Boffa MB; Koschinsky ML
Atherosclerosis; 2018 Aug; 275():11-21. PubMed ID: 29852400
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells.
Romagnuolo R; DeMarco K; Scipione CA; Boffa MB; Koschinsky ML
Thromb Res; 2018 Sep; 169():1-7. PubMed ID: 29990619
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system.
Liu L; Boffa MB; Koschinsky ML
PLoS One; 2013; 8(1):e52287. PubMed ID: 23326327
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein(a): structure-function relationship at the lysine-binding site and plasminogen activator cleavage site.
Anglés-Cano E; Rojas G
Biol Chem; 2002 Jan; 383(1):93-9. PubMed ID: 11928826
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots.
Sangrar W; Koschinsky ML
Biochem Cell Biol; 2000; 78(4):519-25. PubMed ID: 11012092
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of fibrinolysis by lipoprotein(a).
Anglés-Cano E; de la Peña Díaz A; Loyau S
Ann N Y Acad Sci; 2001; 936():261-75. PubMed ID: 11460483
[TBL] [Abstract][Full Text] [Related]
8. Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance.
Hancock MA; Spencer CA; Koschinsky ML
Biochemistry; 2004 Sep; 43(38):12237-48. PubMed ID: 15379562
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.
Hancock MA; Boffa MB; Marcovina SM; Nesheim ME; Koschinsky ML
J Biol Chem; 2003 Jun; 278(26):23260-9. PubMed ID: 12697748
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation.
Feric NT; Boffa MB; Johnston SM; Koschinsky ML
J Thromb Haemost; 2008 Dec; 6(12):2113-20. PubMed ID: 18983515
[TBL] [Abstract][Full Text] [Related]
11. Antifibrinolytic effect of single apo(a) kringle domains: relationship to fibrinogen binding.
Rahman MN; Petrounevitch V; Jia Z; Koschinsky ML
Protein Eng; 2001 Jun; 14(6):427-38. PubMed ID: 11477223
[TBL] [Abstract][Full Text] [Related]
12. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface.
Sangrar W; Gabel BR; Boffa MB; Walker JB; Hancock MA; Marcovina SM; Horrevoets AJ; Nesheim ME; Koschinsky ML
Biochemistry; 1997 Aug; 36(34):10353-63. PubMed ID: 9265615
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules.
Xue S; Green MA; LoGrasso PV; Boettcher BR; Madison EL; Curtiss LK; Miles LA
Thromb Haemost; 1999 Mar; 81(3):428-35. PubMed ID: 10102473
[TBL] [Abstract][Full Text] [Related]
14. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
Hervio L; Chapman MJ; Thillet J; Loyau S; Anglés-Cano E
Blood; 1993 Jul; 82(2):392-7. PubMed ID: 8329699
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments.
Rouy D; Koschinsky ML; Fleury V; Chapman J; Anglés-Cano E
Biochemistry; 1992 Jul; 31(27):6333-9. PubMed ID: 1627572
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway.
Cho T; Jung Y; Koschinsky ML
J Biol Chem; 2008 Nov; 283(45):30503-12. PubMed ID: 18776185
[TBL] [Abstract][Full Text] [Related]
17. Small size apolipoprotein(a) isoforms enhance inflammatory and proteolytic potential of collagen-primed monocytes.
Sabbah N; Jaisson S; Garnotel R; Anglés-Cano E; Gillery P
Lipids Health Dis; 2019 Aug; 18(1):166. PubMed ID: 31470857
[TBL] [Abstract][Full Text] [Related]
18. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a).
Edelstein C; Pfaffinger D; Hinman J; Miller E; Lipkind G; Tsimikas S; Bergmark C; Getz GS; Witztum JL; Scanu AM
J Biol Chem; 2003 Dec; 278(52):52841-7. PubMed ID: 14557258
[TBL] [Abstract][Full Text] [Related]
19. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
Anglés-Cano E; Hervio L; Rouy D; Fournier C; Chapman JM; Laplaud M; Koschinsky ML
Chem Phys Lipids; 1994 Jan; 67-68():369-80. PubMed ID: 8187237
[TBL] [Abstract][Full Text] [Related]
20. Effect of plasminogen activators on human recombinant apolipoprotein(a) having the plasminogen activation cleavage site.
Hervio L; Brunner C; Sorell L; Kang C; Müller H; Anglés-Cano E
Biochim Biophys Acta; 1999 Sep; 1434(1):124-34. PubMed ID: 10556566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
